Establishing a reliable routine is essential for maintaining consistent GLP-1 therapy and achieving optimal treatment outcomes
Clinical decisions should generally rely on established guidance, the laboratorys validated reference interval, and the persons complete cardiovascular-risk profile
Following agonist binding, the GLP-1R is rapidly endocytosed, and whilst active G protein coupled receptors (GPCRs) can continue to generate intracellular signals within the endosomal compartment (Eichel and Zastrow, 2018), the availability of surface GLP-1Rs to extracellular ligand appears to be an important determinant of sustained insulinotropic efficacy in a pharmacological setting (Jones et al., 2018b)
If results continue developing at 1%, maintaining that concentration makes sense until improvements naturally level off
Certain patients, such as those with a hereditary eye condition called Lebers disease, should avoid B12 injections altogether, as these may worsen symptoms
GLP-1 reduces inflammatory markers like C-reactive protein, which promotes HDL dysfunction and atherosclerosis